Atea Pharmaceuticals (AVIR) Gains from Investment Securities (2019 - 2026)

Atea Pharmaceuticals' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $621809.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 28.21% year-over-year to $621809.0; the TTM figure through Mar 2026 stood at $621809.0 (changed N/A YoY), while the FY2025 annual figure was $22.8 million, up 2059.27% from the prior year.
• Gains from Investment Securities was $621809.0 for Q1 2026 at Atea Pharmaceuticals, down from $691762.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $20.2 million in Q3 2024 to a low of $182350.0 in Q3 2022.
• Historically, Gains from Investment Securities has averaged $3.2 million across 5 years, with a median of $724970.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 5037.73% in 2024, then plunged 96.57% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $182350.0 in 2022, then jumped by 9232.23% to $17.0 million in 2023, then tumbled by 93.78% to $1.1 million in 2024, then sank by 34.61% to $691762.0 in 2025, then dropped by 10.11% to $621809.0 in 2026.
• The last three Gains from Investment Securities figures came in at $621809.0 (Q1 2026), $691762.0 (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.